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The Xpert Flu/RSV XC assay was compared to laboratory-developed tests (LDTs) (n  207) and the Xpert Flu assay (n  147)
using archived nasopharyngeal swabs. The percentages of positive agreements with LDTs were 97.8% for influenza A, 97.2% for
influenza B, and 89.3% for RSV. The sensitivity of influenza detection was improved with the Xpert Flu/RSV XC assay compared
to the Xpert Flu assay.
Influenza and respiratory syncytial virus (RSV) are significantcauses of morbidity and mortality in the United States. On av-
erage, between 1997 and 2009, 19,000 deaths were attributable
to influenza and 11,000 were attributable to RSV (1) annually.
The low sensitivity of rapid antigen tests and the delayed time to
result of viral cultures combined with the improved sensitivity
afforded by molecular methods have led to an increase in FDA-
cleared tests and systems designed to detect these viruses (2, 3).
The Xpert Flu/RSV XC assay (Cepheid, Sunnyvale, CA) is a newly
FDA-cleared rapid, random-access molecular test capable of de-
tecting and differentiating influenza A, influenza B, and RSV vi-
ruses from nasal wash fluid samples/aspirates and nasopharyngeal
(NP) swabs. The new Xpert assay allows extraction, amplification,
and detection to take place within a single-use disposable car-
tridge, with results available in 63 min. In addition to expanding
the detection to include RSV, the Xpert Flu/RSV XC assay includes
new and additional primer sets to provide redundant coverage for
the influenza viruses and to minimize the impact of genetic drift.
Workflow was also improved by placing all wet reagents inside the
cartridge, and the extraction was optimized. Given these improve-
ments, we sought to ascertain the performance characteristics of
the Xpert Flu/RSV XC assay, especially compared to the previous
Xpert Flu assay.
We conducted a verification study using archived NP swabs
collected between September 2013 and January 2015 that were
chosen by convenience sampling to enrich for positive samples.
Nasopharyngeal specimens were collected using the Becton Dick-
inson universal viral transport system (Sparks, MD) from patients
exhibiting symptoms of an upper respiratory infection and sub-
mitted to UNC Health Care for testing. Clinical results had been
obtained via the Xpert Flu assay, the Nanosphere Verigene respi-
ratory virus plus (Northbrook, IL), or the GenMark repiratory
viral panel (RVP) (Carlsbad, CA). Sample remnants were stored at
70°C prior to study initiation. The reference method was de-
fined as our laboratory-developed tests (LDTs) for influenza A/B
and RSV, which were performed as previously described (4, 5)
using published primer and probe sequences (6, 7). Influenza A- or
B-positive samples were also tested with the Xpert Flu cartridge if they
were not already tested as part of standard diagnostic testing. The
Xpert Flu/RSV XC and Xpert Flu assays were performed according to
the manufacturer’s instructions with one exception: instead of invert-
ing the sample tube 5 times, it was vortexed for 5 s.
Of the 207 NP swabs tested, 172 were positive by both the Xpert
Flu/RSV XC test and the LDT: 36 influenza A 2009 H1N1, 14
influenza A H3, 39 untyped influenza A, 35 influenza B, 17 RSV A,
and 31 RSV B. Four swabs were positive for both influenza A and
RSV. An additional sample was dually positive only by the LDT;
the Xpert Flu/RSV XC assay was positive for influenza A but did
not detect the RSV. Two swabs were positive by the Xpert Flu/RSV
XC test alone (influenza B, cycle threshold [CT], 35.0; RSV, CT,
35.6), and 7 were positive by the LDT alone (2 influenza A, CT,
34.1, 36.6; 5 RSV, CT range, 36.2 to 38.3). Of the 9 discordant
results, 8 were initially tested with the GenMark RVP assay; each
was positive for the analyte in question, indicating that the Xpert-
only positive results may be true positives. Thirty-one swabs were
negative by both tests, including samples established by the Gen-
Mark assay to be positive for adenovirus (n  2); human metap-
neumovirus (n  1); rhinovirus (n  5); coronaviruses 229E (n 
1), HKU1 (n  3), NL63 (n  1), and OC43 (n  3); and parain-
fluenza viruses 1 to 4 (PIV 1 to 3, n  1 each; PIV 4, n  2). Table
1 shows the performance of the Xpert Flu/RSV XC test compared
with our LDTs. The mean LDT CT value of concordantly positive
samples was 25.5 (95% confidence interval [CI], 24.7, 26.4; range,
15.11 to 39.57), while the mean LDT CT of the 7 samples missed by
the Xpert Flu/RSV XC test was 36.5 (95% CI, 35.3, 37.7; range,
34.06 to 38.32), indicating less strongly positive samples. This dif-
ference was statistically significant (P  0.0001, Student’s t test).
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TABLE 1 Comparison of the Xpert Flu/RSV XC to laboratory-






a Concordant positives: 89 influenza A, 35 influenza B, and 48 RSV positive samples.
b Two false-positive samples: 1 influenza B and 1 RSV.
c Seven false-negative results: 2 influenza A, 2 RSV A, and 3 RSV B positive samples.
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When the new Xpert Flu/RSV XC cartridge was compared to
that of the Xpert Flu assay for the detection of influenza viruses
(n  147) (Table 2), it was found to be slightly simpler (1 set-up
step eliminated), slightly faster (63 versus 75 min), and signifi-
cantly more sensitive (P  0.0002, Fisher’s exact test). When the
CT values of the LDT influenza-positive samples were analyzed,
there was a significant difference between those that were positive
by both the Xpert Flu and Flu/RSV XC cartridges and those that
were positive by the Flu/RSV XC cartridge alone (23.7 versus 34.3;
P  0.0001). The difference between LDT-positive/Xpert Flu/RSV
XC-positive/Xpert Flu-negative (Xpert Flu false negative) and
LDT-positive/Xpert Flu/RSV XC-negative/Xpert Flu-negative
samples (false negative by both Xpert tests) was not significant (CT
34.3 versus 35.3; P  0.57). Notably, of 10 samples collected be-
tween October 2014 and January 2015 that were identified as
falsely negative by Xpert Flu for influenza A/H3 (i.e., positive by
GenMark RVP, negative by Xpert Flu), all were positive by the
Xpert Flu/RSV XC assay.
The overall accuracy of the Xpert Flu/RSV XC assay compared
to the LDT was 95.8% (204/213), with 99.1% (211/213), 99.5%
(212/213), and 97.2% (207/213) accuracy for influenza A, influ-
enza B, and RSV, respectively. The sensitivity/specificity was
97.8%/100% for influenza A, 100%/99.4% for influenza B, and
90.6%/99.4% for RSV. The precision of Xpert Flu/RSV XC results
was evaluated for influenza A/H1N1, influenza A/H3, influenza B,
and RSV using CLSI EP-15 guidelines (8). Daily precision was 0.90
to 2.3 CT, depending on the viral target, while overall precision was
0.81 to 2.1 CT (data not shown). Although the LDT was more
sensitive, particularly for RSV, it is a batched test with a turn-
around time of 8 to 24 h. The Xpert Flu/RSV XC test provides a
result in 63 min. The assay is classified as moderately complex;
setup is simple, taking 2 min, and can be done by nonmolecular
personnel. It does not subtype influenza A or differentiate RSV A
from RSV B, but the sensitivity is significantly improved over the
existing Xpert Flu assay.
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TABLE 2 A subset of the sample bank was used to compare Xpert Flu










a Samples positive by both the Xpert Flu test and the LDT included 34 influenza
A/H1N1, 4 influenza A/H3, 39 influenza A not typed, and 31 influenza B.
b Of those missed by the Xpert Flu test, 4 were influenza A/H1N1-, 10 were influenza
A/H3-, and 4 were influenza B-positive specimens.
c More true-positive samples were detected by the Xpert Flu/RSV XC assay, including
36 influenza A/H1N1-positive, 14 influenza A/H3-positive, 39 influenza A not typed,
and 35 influenza B-positive samples.
d There was 1 influenza B false positive.
e Both Xpert Flu/RSV XC false negatives were influenza A/H1N1-positive samples. One
was collected from an adult 6 days after symptom onset, the other from an adult with
no noted indications of a respiratory infection.
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